Skip to main content

Compare Stocks

Date Range: 

 Dicerna PharmaceuticalsPrestige Consumer HealthcareZentalis PharmaceuticalsArcus BiosciencesCryoport
SymbolNASDAQ:DRNANYSE:PBHNASDAQ:ZNTLNYSE:RCUSNASDAQ:CYRX
Price Information
Current Price$25.93$48.83$55.69$28.09$48.42
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.01.61.41.71.7
Analysis Score4.53.31.53.53.5
Community Score3.02.83.32.52.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.71.7
Earnings & Valuation Score0.61.90.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$42.29$89.60$62.60$51.50$72.57
% Upside from Price Target63.08% upside83.49% upside12.41% upside83.34% upside49.88% upside
Trade Information
Market Cap$2.02 billion$2.42 billion$2.43 billion$2.02 billion$2.28 billion
Beta1.330.76N/A1.261.23
Average Volume793,897490,598297,746531,825593,023
Sales & Book Value
Annual Revenue$23.90 million$963.01 millionN/A$15 million$33.94 million
Price / Sales83.432.53N/A132.9565.17
CashflowN/A$4.75 per shareN/AN/AN/A
Price / CashN/A10.29N/AN/AN/A
Book Value$2.22 per share$23.30 per shareN/A$3.57 per share$3.52 per share
Price / Book11.682.10N/A7.8713.76
Profitability
Net Income$-120,460,000.00$142.28 millionN/A$-84,710,000.00$-18,330,000.00
EPS($1.76)$2.96N/A($1.93)($0.55)
Trailing P/E RatioN/A15.160.00N/AN/A
Forward P/E RatioN/A14.89N/AN/A4,842.00
P/E GrowthN/A2.96N/AN/AN/A
Net Margins-88.81%17.03%N/A-112.63%-55.87%
Return on Equity (ROE)-71.72%13.76%N/A-27.43%-17.68%
Return on Assets (ROA)-16.60%4.80%N/A-20.96%-11.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.22%N/AN/A0.93%
Current Ratio2.62%1.98%N/A4.89%16.13%
Quick Ratio2.62%1.14%N/A4.89%16.09%
Ownership Information
Institutional Ownership Percentage80.64%N/A67.13%60.56%88.29%
Insider Ownership Percentage11.30%1.20%N/A19.71%11.50%
Miscellaneous
Employees302520124236605
Shares Outstanding76.90 million49.91 million41.31 million71.00 million45.68 million
Next Earnings Date8/5/2021 (Estimated)8/5/2021 (Estimated)5/21/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Cryoport, Inc. (NASDAQ:CYRX) Expected to Post Earnings of -$0.13 Per ShareCryoport, Inc. (NASDAQ:CYRX) Expected to Post Earnings of -$0.13 Per Share
americanbankingnews.com - May 16 at 4:06 PM
CryoPort (CYRX) Stock Returns: Average and Excess Return for CYRX after a Fall or Rise - AI Dashboard - TrefisCryoPort (CYRX) Stock Returns: Average and Excess Return for CYRX after a Fall or Rise - AI Dashboard - Trefis
dashboards.trefis.com - May 14 at 1:59 PM
Notable Two Hundred Day Moving Average Cross - CYRXNotable Two Hundred Day Moving Average Cross - CYRX
nasdaq.com - May 13 at 12:07 AM
Needham & Company LLC Boosts Cryoport (NASDAQ:CYRX) Price Target to $77.00Needham & Company LLC Boosts Cryoport (NASDAQ:CYRX) Price Target to $77.00
marketbeat.com - May 11 at 8:41 AM
Needham & Company LLC Raises Cryoport (NASDAQ:CYRX) Price Target to $77.00Needham & Company LLC Raises Cryoport (NASDAQ:CYRX) Price Target to $77.00
americanbankingnews.com - May 11 at 8:37 AM
Cryoport (NASDAQ:CYRX) Trading Down 9.8%Cryoport (NASDAQ:CYRX) Trading Down 9.8%
americanbankingnews.com - May 10 at 5:42 PM
Leerink Partners Stick to Their Buy Rating for CryoPort IncLeerink Partners Stick to Their Buy Rating for CryoPort Inc
investing.com - May 10 at 9:53 AM
Form 4 Cryoport, Inc. For: Apr 30 Filed by: ZECCHINI EDWARD J - StreetInsider.comForm 4 Cryoport, Inc. For: Apr 30 Filed by: ZECCHINI EDWARD J - StreetInsider.com
streetinsider.com - May 7 at 11:39 PM
Cryoport (NASDAQ:CYRX) Rating Increased to Hold at Zacks Investment ResearchCryoport (NASDAQ:CYRX) Rating Increased to Hold at Zacks Investment Research
marketbeat.com - May 7 at 8:15 PM
Q2 2021 Earnings Estimate for Cryoport, Inc. (NASDAQ:CYRX) Issued By SVB LeerinkQ2 2021 Earnings Estimate for Cryoport, Inc. (NASDAQ:CYRX) Issued By SVB Leerink
americanbankingnews.com - May 7 at 7:46 AM
LabConnect, Cryoport Partner To Support Triumvira Trial Logistics - Contract PharmaLabConnect, Cryoport Partner To Support Triumvira Trial Logistics - Contract Pharma
contractpharma.com - May 7 at 12:16 AM
Cryoport sees revenue jump more than 445% during first quarter - Nashville Business Journal - Nashville Business JournalCryoport sees revenue jump more than 445% during first quarter - Nashville Business Journal - Nashville Business Journal
bizjournals.com - May 6 at 7:16 PM
LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - Murfreesboro PostLabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - Murfreesboro Post
murfreesboropost.com - May 6 at 2:15 PM
LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - PRNewswireLabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial - PRNewswire
prnewswire.com - May 6 at 8:38 AM
LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical TrialLabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial
finance.yahoo.com - May 6 at 8:38 AM
Cryoport Inc. (NASDAQ:CYRX) stock surged in the current trading session; here’s why - Market GlobalistCryoport Inc. (NASDAQ:CYRX) stock surged in the current trading session; here’s why - Market Globalist
marketglobalist.com - May 5 at 5:37 PM
What is the Markets View on CryoPort Inc (CYRX) Stocks Price and Volume Trends Wednesday? - InvestorsObserverWhat is the Market's View on CryoPort Inc (CYRX) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
investorsobserver.com - May 5 at 5:37 PM
Cryoport grows revenue 445% | Area Stocks | nashvillepost.com - Nashville PostCryoport grows revenue 445% | Area Stocks | nashvillepost.com - Nashville Post
nashvillepost.com - May 5 at 5:37 PM
Cryoport (NASDAQ:CYRX) PT Raised to $77.00Cryoport (NASDAQ:CYRX) PT Raised to $77.00
americanbankingnews.com - May 5 at 3:27 PM
Cryoport (NASDAQ:CYRX) Shares Gap Up  on Strong EarningsCryoport (NASDAQ:CYRX) Shares Gap Up on Strong Earnings
americanbankingnews.com - May 5 at 11:10 AM
Cryoport (NASDAQ:CYRX) Posts Quarterly  Earnings Results, Beats Estimates By $0.08 EPSCryoport (NASDAQ:CYRX) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS
americanbankingnews.com - May 4 at 11:30 PM
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates - NasdaqCryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
nasdaq.com - May 4 at 11:17 PM
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue EstimatesCryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 4 at 11:17 PM
CryoPort Stock Is Estimated To Be Modestly Undervalued - Yahoo FinanceCryoPort Stock Is Estimated To Be Modestly Undervalued - Yahoo Finance
finance.yahoo.com - May 4 at 6:17 PM
Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 - PRNewswireCryoport Revenue Climbs to $53.3 Million for First Quarter 2021 - PRNewswire
prnewswire.com - May 4 at 6:17 PM
Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021
finance.yahoo.com - May 4 at 6:16 PM
CryoPort Q1 2021 Earnings Preview - Seeking AlphaCryoPort Q1 2021 Earnings Preview - Seeking Alpha
seekingalpha.com - May 3 at 7:56 PM
DateCompanyBrokerageAction
4/22/2021Dicerna PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
4/19/2021Dicerna PharmaceuticalsTruist SecuritiesBoost Price Target
4/13/2021Dicerna PharmaceuticalsSVB LeerinkLower Price Target
3/8/2021Dicerna PharmaceuticalsChardan CapitalBoost Price Target
3/8/2021Dicerna PharmaceuticalsHC WainwrightBoost Price Target
3/1/2021Dicerna PharmaceuticalsB. RileyBoost Price Target
5/12/2020Dicerna PharmaceuticalsRoyal Bank of CanadaInitiated Coverage
5/11/2020Dicerna PharmaceuticalsSunTrust BanksBoost Price Target
5/17/2021Prestige Consumer HealthcareDA DavidsonBoost Price Target
12/2/2020Prestige Consumer HealthcareBMO Capital MarketsUpgrade
11/9/2020Prestige Consumer HealthcareCIBCBoost Price Target
11/6/2020Prestige Consumer HealthcareTD SecuritiesBoost Price Target
6/29/2020Prestige Consumer HealthcareSidotiUpgrade
6/17/2020Prestige Consumer HealthcareOppenheimerReiterated Rating
4/14/2020Prestige Consumer HealthcareJefferies Financial GroupDowngrade
1/19/2021Zentalis PharmaceuticalsWedbushInitiated Coverage
12/16/2020Zentalis PharmaceuticalsMorgan StanleyBoost Price Target
9/28/2020Zentalis PharmaceuticalsCantor FitzgeraldInitiated Coverage
4/28/2020Zentalis PharmaceuticalsGuggenheimInitiated Coverage
2/25/2021Arcus BiosciencesBarclaysBoost Price Target
2/25/2021Arcus BiosciencesMizuhoBoost Price Target
1/20/2021Arcus BiosciencesBenchmarkBoost Price Target
11/24/2020Arcus BiosciencesBerenberg BankInitiated Coverage
11/23/2020Arcus BiosciencesEvercore ISIInitiated Coverage
6/2/2020Arcus BiosciencesCitigroupBoost Price Target
4/16/2020Arcus BiosciencesBTIG ResearchBoost Price Target
5/11/2021CryoportNeedham & Company LLCBoost Price Target
3/22/2021CryoportUBS GroupInitiated Coverage
1/19/2021CryoportKeyCorpBoost Price Target
1/14/2021CryoportRoth CapitalBoost Price Target
8/24/2020CryoportStephensBoost Price Target
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.